al7bebe
عضو نشط
- التسجيل
- 24 مارس 2005
- المشاركات
- 10,052
AETHLON MEDICAL INC(OTC BB: AEMD.OB )
Last Trade: 0.1140
Trade Time: 12:42PM EDT
Change: 0.0570 (100.00%)
Prev Close: 0.06
Open: 0.08
Bid: 0.07 x 30000
Ask: 0.20 x 5000
1y Target Est: 1.00
Day's Range: 0.06 - 0.1140
52wk Range: 0.04 - 0.32
Volume: 1,667,866
Avg Vol (3m): 205,382
Market Cap: 11.41M
P/E (ttm): N/A
EPS (ttm): -0.06
Div & Yield:
نازل خبر السهم ممكن نشوف اسعار اكثر
Aethlon Medical Receives Government Contract Award from DARPA
Contract Program Will Support The Development of an Aethlon ADAPT Sepsis Prevention Device
SAN DIEGO, Oct. 3, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB:AEMD.ob - News), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has been awarded a $6.8 million contract from the Defense Advanced Research Projects Agency (DARPA) to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers. The contract program will utilize the Aethlon ADAPT™ system as a core technology component underlying an extracorporeal blood purification device that selectively clears multiple sepsis-enabling particles from circulation to promote recovery and prevent sepsis. The resulting device, which is being advanced under DARPA's Dialysis Like Therapeutics (DLT) program, is expected to dramatically decrease the morbidity and mortality of sepsis, thereby saving thousands of lives and billions of dollars in the United States each year. Under the DLT program, Aethlon will also introduce a novel blood pump strategy to reduce or eliminate the systemic administration of anticoagulants normally required during extracorporeal device therapies. Worldwide, more than 18 million cases of sepsis are reported every year, with more than six million resulting in death.
(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)
"We are truly honored to receive this contract award and look forward to working with DARPA and other DLT team participants to advance this important therapeutic endeavor," stated Aethlon Medical Chairman and CEO, Jim Joyce. "The award also reinforces the expansive capabilities of our ADAPT™ system, increases the breadth of our product pipeline, and transitions us from a development-stage to revenue-stage organization."
The Aethlon ADAPT™ system, introduced earlier this year, is an adaptive dialysis-like affinity platform technology that provides the foundation for a new class of therapeutics that selectively target the clearance of harmful agents from the entire circulatory system without the loss of essential blood components. Therapies that evolve from the Aethlon ADAPT™ system overcome the historic limitation of extracorporeal strategies that indiscriminately adsorb or remove particles solely by molecule size. In function, the device platform allows the immobilization of single or multiple affinity drug agents in the outer-capillary space of plasma membrane technology as a means to provide rapid real-time clearance of corresponding targets without adding drug toxicity or interaction risks to established therapies. Beyond providing a novel regulatory and commercialization pathway for affinity drug agents, Aethlon ADAPT™ therapies can be implemented for use within the global infrastructure of dialysis machines and CRRT systems already located in hospitals and clinics. As Aethlon advances its current pipeline of therapies toward market, the company will seek to further leverage its ADAPT™ system to generate revenue through future government contracts or grants, and collaborations with organizations representing the pharmaceutical, biotechnology and medical device industry. The Aethlon award from DARPA is a fixed price five-year contract valued at $6,794,389 with year one revenues of approximately $2 million.
Last Trade: 0.1140
Trade Time: 12:42PM EDT
Change: 0.0570 (100.00%)
Prev Close: 0.06
Open: 0.08
Bid: 0.07 x 30000
Ask: 0.20 x 5000
1y Target Est: 1.00
Day's Range: 0.06 - 0.1140
52wk Range: 0.04 - 0.32
Volume: 1,667,866
Avg Vol (3m): 205,382
Market Cap: 11.41M
P/E (ttm): N/A
EPS (ttm): -0.06
Div & Yield:
نازل خبر السهم ممكن نشوف اسعار اكثر
Aethlon Medical Receives Government Contract Award from DARPA
Contract Program Will Support The Development of an Aethlon ADAPT Sepsis Prevention Device
SAN DIEGO, Oct. 3, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB:AEMD.ob - News), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has been awarded a $6.8 million contract from the Defense Advanced Research Projects Agency (DARPA) to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers. The contract program will utilize the Aethlon ADAPT™ system as a core technology component underlying an extracorporeal blood purification device that selectively clears multiple sepsis-enabling particles from circulation to promote recovery and prevent sepsis. The resulting device, which is being advanced under DARPA's Dialysis Like Therapeutics (DLT) program, is expected to dramatically decrease the morbidity and mortality of sepsis, thereby saving thousands of lives and billions of dollars in the United States each year. Under the DLT program, Aethlon will also introduce a novel blood pump strategy to reduce or eliminate the systemic administration of anticoagulants normally required during extracorporeal device therapies. Worldwide, more than 18 million cases of sepsis are reported every year, with more than six million resulting in death.
(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)
"We are truly honored to receive this contract award and look forward to working with DARPA and other DLT team participants to advance this important therapeutic endeavor," stated Aethlon Medical Chairman and CEO, Jim Joyce. "The award also reinforces the expansive capabilities of our ADAPT™ system, increases the breadth of our product pipeline, and transitions us from a development-stage to revenue-stage organization."
The Aethlon ADAPT™ system, introduced earlier this year, is an adaptive dialysis-like affinity platform technology that provides the foundation for a new class of therapeutics that selectively target the clearance of harmful agents from the entire circulatory system without the loss of essential blood components. Therapies that evolve from the Aethlon ADAPT™ system overcome the historic limitation of extracorporeal strategies that indiscriminately adsorb or remove particles solely by molecule size. In function, the device platform allows the immobilization of single or multiple affinity drug agents in the outer-capillary space of plasma membrane technology as a means to provide rapid real-time clearance of corresponding targets without adding drug toxicity or interaction risks to established therapies. Beyond providing a novel regulatory and commercialization pathway for affinity drug agents, Aethlon ADAPT™ therapies can be implemented for use within the global infrastructure of dialysis machines and CRRT systems already located in hospitals and clinics. As Aethlon advances its current pipeline of therapies toward market, the company will seek to further leverage its ADAPT™ system to generate revenue through future government contracts or grants, and collaborations with organizations representing the pharmaceutical, biotechnology and medical device industry. The Aethlon award from DARPA is a fixed price five-year contract valued at $6,794,389 with year one revenues of approximately $2 million.